- Home
- ACCS vs ALGS Comparison
ACCS vs ALGS Comparison
Compare ACCS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- ALGS
- Stock Information
- Founded
- ACCS 1988
- ALGS 2018
- Country
- ACCS United States
- ALGS United States
- Employees
- ACCS N/A
- ALGS N/A
- Industry
- ACCS Publishing
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- ACCS Consumer Discretionary
- ALGS Health Care
- Exchange
- ACCS Nasdaq
- ALGS Nasdaq
- Market Cap
- ACCS 44.2M
- ALGS 50.4M
- IPO Year
- ACCS N/A
- ALGS 2020
- Fundamental
- Price
- ACCS $11.75
- ALGS $8.46
- Analyst Decision
- ACCS Strong Buy
- ALGS Strong Buy
- Analyst Count
- ACCS 1
- ALGS 1
- Target Price
- ACCS $15.00
- ALGS $70.00
- AVG Volume (30 Days)
- ACCS 10.0K
- ALGS 101.5K
- Earning Date
- ACCS 08-07-2025
- ALGS 08-05-2025
- Dividend Yield
- ACCS N/A
- ALGS N/A
- EPS Growth
- ACCS N/A
- ALGS N/A
- EPS
- ACCS N/A
- ALGS N/A
- Revenue
- ACCS $22,961,000.00
- ALGS $3,270,000.00
- Revenue This Year
- ACCS $7.67
- ALGS N/A
- Revenue Next Year
- ACCS N/A
- ALGS $51.55
- P/E Ratio
- ACCS N/A
- ALGS N/A
- Revenue Growth
- ACCS 6.92
- ALGS N/A
- 52 Week Low
- ACCS $7.79
- ALGS $3.76
- 52 Week High
- ACCS $13.35
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- ACCS N/A
- ALGS 63.36
- Support Level
- ACCS N/A
- ALGS $6.82
- Resistance Level
- ACCS N/A
- ALGS $9.10
- Average True Range (ATR)
- ACCS 0.00
- ALGS 0.75
- MACD
- ACCS 0.00
- ALGS 0.08
- Stochastic Oscillator
- ACCS 0.00
- ALGS 86.38
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.